Patents Assigned to Cellegy Pharmaceuticals, Inc.
-
Patent number: 7157097Abstract: This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.Type: GrantFiled: March 12, 2003Date of Patent: January 2, 2007Assignee: Cellegy Pharmaceuticals Inc.Inventors: Vivien H. W. Mak, Stephen Grayson
-
Publication number: 20060198883Abstract: Compositions and methods for the treatment of anorectal disorders are provided in which certain combinations of NO donors, PDE inhibitors, superoxide (O2?) scavengers, ?-adrenergic agonists, cAMP-dependent protein kinase activators, ?1-adrenergic antagonists, L-type Ca2+ channel blockers, estrogens, ATP-sensitive K+ channel activators and smooth muscle relaxants are used.Type: ApplicationFiled: February 16, 2006Publication date: September 7, 2006Applicant: Cellegy Pharmaceuticals, Inc.Inventors: Thomas Parks, Vivien Mak, Jung-Chung Lee, Charles Lee
-
Publication number: 20060030622Abstract: The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and/or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic disorders, using a variety of compounds, including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators, ?-adrenergic receptor antagonists, ?-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g.Type: ApplicationFiled: September 26, 2005Publication date: February 9, 2006Applicant: Cellegy Pharmaceuticals, Inc.Inventors: Vivien Mak, Stephen Grayson
-
Patent number: 6987129Abstract: The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and/or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic disorders, using a variety of compounds, including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators, ?-adrenergic receptor antagonists, ?-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g.Type: GrantFiled: March 6, 2002Date of Patent: January 17, 2006Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Vivien H. W. Mak, Stephen Grayson
-
Patent number: 6946484Abstract: Methods and formulations for inhibiting and preventing a malignant cell phenotype by administering to cells a low dose of a nitric oxide mimetic are provided.Type: GrantFiled: April 26, 2001Date of Patent: September 20, 2005Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Michael A. Adams, Charles H. Graham, Jeremy P. W. Heaton, Lynne-Marie Postovit
-
Publication number: 20050197300Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to 1/20) of those known to induce vasodilation in “normal” circulations.Type: ApplicationFiled: June 11, 2003Publication date: September 8, 2005Applicants: Cellegy Pharmaceuticals Inc., Queen's University at KingstonInventors: Michael Adams, Jeremy Heaton, James Banting
-
Patent number: 6889875Abstract: A dispensing device includes a hollow body coupled to a pump mechanism having a dip tube, and to a follower piston. A well provided in the piston is generally larger in diameter than the dip tube to allow fluid in the chamber to flow down into the well as the dip tube enters the well to facilitate fluid removal after a significant portion of the fluid has been removed.Type: GrantFiled: July 15, 2002Date of Patent: May 10, 2005Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Charles E. Lee, Jung-Chung Lee
-
Publication number: 20050075391Abstract: A pharmaceutical composition contains a nitric oxide donor and advantageously an optional corticosteroid and/or topical anesthetic. The composition is useful in a method for treating anal disorders such as anal fissure, anal ulcer, hemorrhoidal disease, levator spasm, and so forth, by topical application to or proximate the affected area.Type: ApplicationFiled: September 22, 2003Publication date: April 7, 2005Applicant: Cellegy Pharmaceuticals, Inc.Inventor: Stephen Gorfine
-
Patent number: 6869961Abstract: The present invention provides store operated calcium influx inhibitor compounds, pharmaceutical compositions, and methods of use. The compounds are useful for treating an inflammatory disease or treating an inflammatory reaction. Preferably, compounds, compositions and methods of this invention are used for treatment of inflammatory skin, pulmonary, musculoskeletal, and gastrointestinal diseases, as well as autoimmune disorders, transplantation treatment, and osteoporosis.Type: GrantFiled: September 24, 2003Date of Patent: March 22, 2005Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Thomas P. Parks, Don R. Baker
-
Publication number: 20040234619Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.Type: ApplicationFiled: June 15, 2004Publication date: November 25, 2004Applicant: Cellegy Pharmaceuticals, Inc.Inventors: Michael A. Adams, Jeremy P.W. Heaton
-
Patent number: 6787553Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.Type: GrantFiled: July 9, 2002Date of Patent: September 7, 2004Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Michael A. Adams, Jeremy P. W. Heaton
-
Publication number: 20040166176Abstract: In the field of treatment of erectile dysfunction there is disclosed a novel therapy in which the actions of an agent or agents, produce a combination of effects to induce effective erection (and avoid priapism) while reducing or entirely avoiding pain. The method taught combines a first action of an agent which is to antagonize a drug-induced pain stimulus within nociceptive nerves of penile tissue with a second action of either the same agent or of a second agent, which enhances, synergistically, smooth muscle relaxation. The synergism allows for at least an equivalent effect of smooth muscle relaxation to be obtained at significantly lower doses of a smooth muscle relaxing agent such as PGE1 which in standard therapy is also in 40-45% of cases pain-inducing at doses which achieve effective erection.Type: ApplicationFiled: February 23, 2004Publication date: August 26, 2004Applicant: Cellegy Pharmaceuticals Inc.Inventors: Michael A. Adams, Jeremy P.W. Heaton, Donald H. Maurice
-
Patent number: 6747063Abstract: In the field of treatment of erectile dysfunction there is disclosed a novel therapy in which the actions of an agent or agents, produce a combination of effects to induce effective erection (and avoid priapism) while reducing or entirely avoiding pain. The method taught combines a first action of an agent which is to antagonize a drug-induced pain stimulus within nociceptive nerves of penile tissue with a second action of either the same agent or of a second agent, which enhances, synergistically, smooth muscle relaxation. The synergism allows for at least an equivalent effect of smooth muscle relaxation to be obtained at significantly lower doses of a smooth muscle relaxing agent such as PGE1 which in standard therapy is also in 40-45% of cases pain-inducing at doses which achieve effective erection.Type: GrantFiled: October 23, 1998Date of Patent: June 8, 2004Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Michael A. Adams, Jeremy P. W. Heaton, Donald H. Maurice
-
Publication number: 20040106537Abstract: The present invention provides store operated calcium influx inhibitor compounds, pharmaceutical compositions, and methods of use. The compounds are useful for treating an inflammatory disease or treating an inflammatory reaction. Preferably, compounds, compositions and methods of this invention are used for treatment of inflammatory skin, pulmonary, musculoskeletal, and gastrointestinal diseases, as well as autoimmune disorders, transplantation treatment, and osteoporosis.Type: ApplicationFiled: September 24, 2003Publication date: June 3, 2004Applicant: Cellegy Pharmaceuticals, Inc.Inventors: Thomas P. Parks, Don R. Baker
-
Patent number: 6699886Abstract: The present invention provides store operated calcium influx inhibitor compounds, pharmaceutical compositions, and methods of use. The compounds are useful for treating an inflammatory disease or treating an inflammatory reaction. Preferably, compounds, compositions and methods of this invention are used for treatment of inflammatory skin, pulmonary, musculoskeletal, and gastrointestinal diseases, as well as autoimmune disorders, transplantation treatment, and osteoporosis.Type: GrantFiled: May 31, 2002Date of Patent: March 2, 2004Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Thomas P. Parks, Don R. Baker
-
Publication number: 20030222105Abstract: A dispensing device includes a hollow body coupled to a pump mechanism having a dip tube, and to a follower piston. A well provided in the piston is generally larger in diameter than the dip tube to allow fluid in the chamber to flow down into the well as the dip tube enters the well to facilitate fluid removal after a significant portion of the fluid has been removed.Type: ApplicationFiled: July 15, 2002Publication date: December 4, 2003Applicant: Cellegy Pharmaceuticals, Inc.Inventors: Charles E. Lee, J. C. Lee
-
Patent number: 6627632Abstract: Compositions and methods for the treatment of anorectal disorders are provided in which certain combinations of NO donors, PDE inhibitors, superoxide (O2−) scavengers, &bgr;-adrenergic agonists, cAMP-dependent protein kinase activators, &agr;1-adrenergic antagonists, L-type Ca2+ channel blockers, estrogens, ATP-sensitive K+ channel activators and smooth muscle relaxants are used.Type: GrantFiled: July 30, 2001Date of Patent: September 30, 2003Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Thomas P. Parks, Vivien Mak, Jung-Chung Lee, Charles Lee
-
Publication number: 20030175329Abstract: Semisolid topical pharmaceutical compositions comprising a therapeutically effective amount of a mammalian hormone and an effective amount of a penetration enhancer and methods for their use are provided. The pharmaceutical compositions and methods for their use can provide blood or plasma levels of the administered hormone within a predetermined or normal range of hormone values. In particular embodiments, the hormone is testosterone or estrogen and the amount to be applied to the skin of the subject is determined according to the weight or body mass index of the subject. The topical composition can be formulated in solutions, creams, lotions, ointments, and gels.Type: ApplicationFiled: October 4, 2002Publication date: September 18, 2003Applicant: Cellegy Pharmaceuticals, Inc.Inventors: Daniel L. Azarnoff, Vivien H.W. Mak
-
Publication number: 20030166625Abstract: This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.Type: ApplicationFiled: March 12, 2003Publication date: September 4, 2003Applicant: CELLEGY PHARMACEUTICALS INC.Inventors: Vivien H.W. Mak, Stephen Grayson
-
Publication number: 20030114353Abstract: The present invention provides store operated calcium influx inhibitor compounds, pharmaceutical compositions, and methods of use. The compounds are useful for treating an inflammatory disease or treating an inflammatory reaction. Preferably, compounds, compositions and methods of this invention are used for treatment of inflammatory skin, pulmonary, musculoskeletal, and gastrointestinal diseases, as well as autoimmune disorders, transplantation treatment, and osteoporosis.Type: ApplicationFiled: May 31, 2002Publication date: June 19, 2003Applicant: Cellegy Pharmaceuticals, IncInventors: Thomas P. Parks, Don R. Baker